Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Steven Ernest

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Current Medical Research and Opinion|September 13, 2008
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrelDavid S Small, Nagy A Farid, Ying G Li, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2023
Donanemab exposure and efficacy relationship using modeling in Alzheimer's diseaseIvelina Gueorguieva, Brian A Willis, Laiyi Chua, et al.
Journal of Clinical Pharmacology|December 21, 2007
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humansNagy A Farid, Christopher D Payne, C Steven Ernest, et al.
Clinical Pharmacology and Therapeutics|February 22, 2023
Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's DiseaseIvelina Gueorguieva, Brian A Willis, Laiyi Chua, et al.
Journal of Clinical Pharmacology|April 23, 2010
Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agentDavid S Small, Ying G Li, C Steven Ernest, et al.
Drugs & Aging|September 5, 2009
Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trialDavid S Small, Rebecca E Wrishko, C Steven Ernest, et al.
Journal of Cardiovascular Pharmacology|November 22, 2007
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrelChristopher D Payne, Ying Grace Li, David S Small, et al.
Platelets|July 29, 2009
Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjectsYing G Li, Lan Ni, John T Brandt, et al.
Journal of Clinical Pharmacology|June 2, 2011
Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudyJeffrey S Riesmeyer, Daniel E Salazar, Govinda J Weerakkody, et al.
Pharmacotherapy|November 26, 2008
Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjectsNagy A Farid, David S Small, Christopher D Payne, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Current Medical Research and Opinion|September 13, 2008
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrelDavid S Small, Nagy A Farid, Ying G Li, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2023
Donanemab exposure and efficacy relationship using modeling in Alzheimer's diseaseIvelina Gueorguieva, Brian A Willis, Laiyi Chua, et al.
Journal of Clinical Pharmacology|December 21, 2007
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humansNagy A Farid, Christopher D Payne, C Steven Ernest, et al.
Clinical Pharmacology and Therapeutics|February 22, 2023
Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's DiseaseIvelina Gueorguieva, Brian A Willis, Laiyi Chua, et al.
Journal of Clinical Pharmacology|April 23, 2010
Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agentDavid S Small, Ying G Li, C Steven Ernest, et al.
Drugs & Aging|September 5, 2009
Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trialDavid S Small, Rebecca E Wrishko, C Steven Ernest, et al.
Journal of Cardiovascular Pharmacology|November 22, 2007
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrelChristopher D Payne, Ying Grace Li, David S Small, et al.
Platelets|July 29, 2009
Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjectsYing G Li, Lan Ni, John T Brandt, et al.
Journal of Clinical Pharmacology|June 2, 2011
Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudyJeffrey S Riesmeyer, Daniel E Salazar, Govinda J Weerakkody, et al.
Pharmacotherapy|November 26, 2008
Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjectsNagy A Farid, David S Small, Christopher D Payne, et al.
Pageof 3